Display Settings:

Format

Send to:

Choose Destination
    Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50. Epub 2010 Jun 8.

    Resistance to HIV-1 integrase inhibitors: A structural perspective.

    Source

    LBPA, CNRS, Ecole Normale Supérieure de Cachan, Cachan cedex, France. mouscadet@lbpa.ens-cachan.fr

    Abstract

    Strand-transfer inhibitors, of which raltegravir, elvitegravir and S/GSK1349572, is a new class of antiretrovirals that inhibit HIV integrase-catalyzed insertion of the HIV-1 genome into cell chromosomes. The results of clinical trials were very encouraging regarding their viral efficiency and tolerance. However resistance mutations were identified in patients failing to respond to treatment with these inhibitors, involving primary mutations as well as numerous secondary mutations. This review focuses on recent advanced computational studies that have highlighted the contribution of those residues subject to primary mutations and the role of conformational flexibility of the enzyme in binding to strand-transfer inhibitors.

    Copyright © 2010 Elsevier Ltd. All rights reserved.

    PMID:
    20570551
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk